Giles Wilson Purchases 233 Shares of Dr. Martens (LON:DOCS) Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson bought 233 shares of Dr. Martens stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of GBX 64 per share, for a total transaction of £149.12.

Giles Wilson also recently made the following trade(s):

• On Tuesday, April 14th, Giles Wilson purchased 232 shares of Dr. Martens stock. The stock was acquired at an average cost of GBX 65 per share, with a total value of £150.80.

Dr. Martens Price Performance

Shares of DOCS stock opened at GBX 63.10 on Thursday. Dr. Martens plc has a fifty-two week low of GBX 53.05 and a fifty-two week high of GBX 100.87. The firm has a market capitalization of £610.30 million, a price-to-earnings ratio of 37.12, a PEG ratio of 6.40 and a beta of 0.24. The company has a debt-to-equity ratio of 120.66, a quick ratio of 1.13 and a current ratio of 2.18. The stock’s 50-day simple moving average is GBX 64.08 and its 200-day simple moving average is GBX 72.13.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DOCS. Royal Bank Of Canada reissued a “sector perform” rating on shares of Dr. Martens in a research report on Tuesday, February 3rd. Berenberg Bank reiterated a “buy” rating and set a GBX 114 price objective on shares of Dr. Martens in a research note on Wednesday, May 6th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of GBX 3,057.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.